Rat & Mouse Model Market - Global Forecast 2025-2032

Senior leaders in preclinical research leverage the rat and mouse model market for operational excellence, risk mitigation, and strategic agility. By deploying advanced animal models, organizations drive scientific progress and adapt to evolving compliance requirements, positioning themselves for sustainable growth in a dynamic industry environment.

Market Snapshot: Rat and Mouse Model Market Size and Growth

The global rat and mouse model market reached a value of USD 2.45 billion in 2024 and is projected to exceed USD 4.74 billion by 2032, with a compound annual growth rate of 8.56%. This substantial growth trajectory is propelled by the increasing reliance of pharmaceutical and biotechnology firms on animal models for preclinical drug development. Technological advancements, such as gene editing and next-generation phenotyping, are modernizing laboratory workflows. These innovations allow research teams to rapidly align with new scientific methods and dynamic regulatory requirements, ensuring that organizations can respond efficiently to industry changes while fostering ongoing innovation.

Scope & Segmentation of the Rat and Mouse Model Market

The rat and mouse model market spans a diverse range of segments, providing senior executives with the granular data needed for informed resource allocation and efficient procurement.

• Animal Type: Selecting between rats and mice is vital for replicating human physiology, ensuring translational value across disease categories.
• Model Type: Offers genetically modified, disease-specific, knockout, transgenic, and xenograft options to support oncology, neurology, cardiology, and infectious disease studies.
• Application: Facilitates in-depth research in areas such as cancer, immunology, metabolic disorders, orthopedics, neurological, and infectious diseases, enabling cross-disciplinary advancements.
• End User: Academic institutions, contract research organizations, and biopharmaceutical enterprises utilize animal models to advance their research pipelines while maintaining high compliance standards.
• Distribution Channel: Includes both direct and distributor-based access, supporting scalable and secure supply chain strategies.
• Research Type: Encompasses pharmacokinetics, efficacy analysis, behavioral studies, toxicity, and safety evaluations critical across all stages of drug development.
• Service Type: Providers offer both standard and tailored services, supporting teams in meeting unique project goals and evolving research demands rapidly.
• Geography: Regional dynamics influence market strategies, with factors such as regulatory frameworks, innovation adoption, and supply chain stability shaping decision-making in the Americas, Europe, Middle East, Africa, and Asia-Pacific.
• Key Companies: Major players include Charles River Laboratories International, Envigo RMS, Taconic Biosciences, The Jackson Laboratory, Janvier Labs, Biocytogen Pharmaceuticals, Oriental BioService, Crown Bioscience International, GemPharmatech, and TransTech Pharma.

Key Takeaways for Senior Leaders

• Deploying animal models streamlines preclinical workflows and ensures alignment with shifting compliance standards, supporting a proactive approach to risk.
• Innovative gene editing tools, including CRISPR, enable creation of highly targeted disease models, increasing flexibility and responsiveness in research design.
• Utilization of artificial intelligence in phenotyping and imaging enhances data quality, giving research teams greater program visibility and analytic power.
• Integrated laboratory service offerings support seamless transitions from research objectives to operational execution, delivering transparency and lifecycle oversight.
• Locally-based breeding programs and tailored supply chains reduce exposure to global risks while maintaining compliance with regional standards.
• Collaboration with academic partners and specialized contract research organizations enhances expertise and offers differentiation within a complex market landscape.

Tariff Impact on Sourcing and Supply Chains

Recent U.S. tariffs on laboratory animal imports have made sourcing specialized rodent models more complex. To overcome these challenges, organizations are expanding domestic breeding programs, strengthening partnerships with domestic suppliers, and developing adaptive procurement processes. These adjustments help maintain a consistent supply and safeguard compliance in the face of global trade changes.

Methodology & Data Sources

The report is underpinned by secondary research, regulatory analysis, and interviews with contract research organization leaders. Proprietary data and verified international trade records contribute to a robust and comprehensive analysis of the animal model sector.

Why This Report Matters for Decision-Makers

• Delivers actionable insights blending strategic, operational, and regulatory perspectives for the evolving rat and mouse model market.
• Guides executives on managing research continuity and addressing supply chain vulnerabilities in fast-changing preclinical settings.
• Supports leadership in building responsive research strategies that adapt to scientific and compliance shifts in real time.

Conclusion

Senior executives can confidently use this report to guide preclinical strategy, strengthen operational delivery, and support informed, data-driven decisions as the rat and mouse model market continues to advance.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.